Community- and hospital-acquired infections with oseltamivir- and peramivir-resistant influenza A(H1N1)pdm09 viruses during the 2015–2016 season in Japan

Simple item page
dc.contributor.authorHibino, Akinobu
dc.contributor.authorKondo, Hiroshi
dc.contributor.authorMasaki, Hironori
dc.contributor.authorTanabe, Yoshinari
dc.contributor.authorSato, Isamu
dc.contributor.authorTakemae, Nobuhiro
dc.contributor.authorSaito, Takehiko Saito
dc.contributor.authorZaraket, Hassan
dc.contributor.authorSaito, Reiko
dc.contributor.departmentPathology and Laboratory Medicine
dc.contributor.departmentSpecialized Clinical Programs and Services
dc.contributor.departmentCenter for Infectious Diseases Research
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:09:56Z
dc.date.available2025-01-24T12:09:56Z
dc.date.issued2017
dc.description.abstractWe report five cases of community- and hospital-acquired infections with oseltamivir- and peramivir-resistant A(H1N1)pdm09 viruses possessing the neuraminidase (NA) H275Y mutation during January–February 2016 in Japan. One case was hospitalized and was receiving oseltamivir for prophylaxis. The remaining four cases were not taking antiviral drugs at the time of sampling. These cases were geographically distant and epidemiologically unrelated. The five viruses showed ~300-fold rise in IC50 values against oseltamivir and peramivir, defined as highly reduced inhibition according to the WHO definition. Overall, the prevalence of the H275Y A(H1N1)pdm09 viruses was 1.8 % (5/282). The resistant viruses possessed the V241I, N369 K, and N386 K substitutions in the NA that have been previously reported among A(H1N1)pdm09 to alter transmission fitness. Analysis of Michaelis constant (Km) revealed that two of the isolates had reduced NA affinity to MUNANA, while the other three isolates displayed a slightly decreased affinity compared to the sensitive viruses. Further studies are needed to monitor the community spread of resistant viruses and to assess their transmissibility. © 2016, The Author(s).
dc.identifier.doihttps://doi.org/10.1007/s11262-016-1396-9
dc.identifier.eid2-s2.0-84990852998
dc.identifier.pmid27714496
dc.identifier.urihttp://hdl.handle.net/10938/32192
dc.language.isoen
dc.publisherSpringer New York LLC
dc.relation.ispartofVirus Genes
dc.sourceScopus
dc.subjectAntiviral drug susceptibility
dc.subjectCommunity transmission
dc.subjectEnzymatic property
dc.subjectInfluenza virus a(h1n1)pdm09
dc.subjectNeuraminidase
dc.subjectOseltamivir resistant
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectChild
dc.subjectChild, preschool
dc.subjectCommunity-acquired infections
dc.subjectCross infection
dc.subjectCyclopentanes
dc.subjectDrug resistance, viral
dc.subjectFemale
dc.subjectGenes, viral
dc.subjectGuanidines
dc.subjectHumans
dc.subjectInfant
dc.subjectInfluenza a virus, h1n1 subtype
dc.subjectInfluenza, human
dc.subjectJapan
dc.subjectMale
dc.subjectMiddle aged
dc.subjectMutation
dc.subjectOseltamivir
dc.subjectPhylogeny
dc.subjectSeasons
dc.subjectYoung adult
dc.subjectHemagglutinin
dc.subjectLaninamivir
dc.subjectPeramivir
dc.subjectSialidase
dc.subjectZanamivir
dc.subjectCyclopentane derivative
dc.subjectGuanidine derivative
dc.subjectAntiviral resistance
dc.subjectArticle
dc.subjectCancer recurrence
dc.subjectClinical article
dc.subjectCommunity acquired infection
dc.subjectCoughing
dc.subjectDisease predisposition
dc.subjectDisease transmission
dc.subjectDrug dose reduction
dc.subjectFever
dc.subjectGene sequence
dc.subjectHa gene
dc.subjectHospital admission
dc.subjectHospital discharge
dc.subjectHospital infection
dc.subjectHuman
dc.subjectHuman tissue
dc.subjectIc50
dc.subjectInfluenza a (h1n1)
dc.subjectInfluenza a virus (a/kyoto/15k029/2016(h1n1))
dc.subjectInfluenza a virus (a/nagasaki-isahaya/15i007/2016(h1n1))
dc.subjectInfluenza a virus (a/nagasaki/15n002/2016(h1n1))
dc.subjectInfluenza a virus (a/nagasaki/15n005/2016(h1n1))
dc.subjectInfluenza a virus (a/nagasaki/15n011/2016(h1n1))
dc.subjectInfluenza a virus (a/nagasaki/15n026/2016(h1n1))
dc.subjectInfluenza a virus (a/niigata/15f185/2016(h1n1))
dc.subjectInfluenza a virus (a/niigata/15f255/2016(h1n1))
dc.subjectInfluenza a virus (a/niigata/15f341/2016(h1n1))
dc.subjectInfluenza a virus (a/niigata/15nu001/2016(h1n1))
dc.subjectInfluenza a virus (a/perth/261/2009(h1n1))
dc.subjectInfluenza a virus (a/perth/265/2009(h1n1))
dc.subjectInfluenza a virus (h1n1)
dc.subjectMultiple myeloma
dc.subjectNa gene
dc.subjectNasopharyngeal aspiration
dc.subjectNonhuman
dc.subjectPreschool child
dc.subjectRapid influenza antigen detection test
dc.subjectRapid test
dc.subjectReal time polymerase chain reaction
dc.subjectSeasonal variation
dc.subjectVirus isolation
dc.subjectVirus strain
dc.subjectDrug effects
dc.subjectGenetics
dc.subjectSeason
dc.subjectVirology
dc.subjectVirus gene
dc.titleCommunity- and hospital-acquired infections with oseltamivir- and peramivir-resistant influenza A(H1N1)pdm09 viruses during the 2015–2016 season in Japan
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2017-4609.pdf
Size:
465.86 KB
Format:
Adobe Portable Document Format
Download

Collections

Pathology and Laboratory Medicine
Specialized Clinical Programs and Services